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Editorial on the Research Topic
Aurora Kinases: Classical Mitotic Roles, Non-Canonical Functions and Translational Views
Aurora kinases are key mitotic regulators that have also been associated with tumor development and 
progression. The interest on this highly conserved family of protein kinases has grown exponentially 
since they were discovered in the 1990s. Despite the steady increase in the number of laboratories 
involved and the consequent boost of the volume of research output during the last years, the study 
of Aurora kinases remains a very dynamic area in which new discoveries frequently keep coming to 
light. From a clinical perspective, the interest on Aurora kinase biology stems from their identifica-
tion as targets for drug development; an increasing number of Aurora kinase inhibitors are being 
tested in preclinical projects and clinical trials. In this Frontiers Research Topic, we have aimed to 
not only review and revisit different aspects of the functions and regulation of Aurora kinases but 
also provide a forum for the publication of new developments in the field. We have been privileged 
to count on contributions from authors and reviewers that include some of the most experienced 
voices in our research area.
In their introductory article to the Research Topic, two old-timers in the field, David Glover and 
Bill Earnshaw, have provided a historical perspective of Aurora Kinase research. By looking at the 
field’s origin using genetic screens in Drosophila and yeast and cell biological studies in vertebrates 
that led to the identification of Aurora kinases and their partner proteins, the authors give us a unique 
first witness account of the development of the field (Carmena et al.).
Several articles in this Research Topic focus exclusively upon a single member of the Aurora kinase 
family. Among the contributions focused on Aurora A, Garrido and Vernos review the regulation of 
this kinase by TPX2, discussing its relevance as well as its (weak) conservation throughout evolution 
and potential key role in tumorigenesis. Two manuscripts from the Guarguaglini and Medema labs 
explore the interplay between Aurora A kinase and PLK1 and how this contributes to the regulation 
of different processes in mitosis (Asteriti et al.; Bruinsma et al.). Moving forward to the final stage 
of mitosis, Reboutier et al. report on the emerging role of Aurora A on the regulation of mitotic 
exit. The Research Topic also explores the mitotic and non-mitotic roles of Aurora A in the context 
of oncogenic transformation and tumor progression (D’Assoro et al.); this includes a review on the 
interactions between the kinase and the tumor suppressor p53 and the possible consequences for 
their signaling pathways in tumor cells (Sasai et al.). Finally, we have a report on recently described 
non-canonical roles of Aurora A kinase in DNA replication (Tsunematsu et al.).
On the other side of the coin, among the articles focusing upon Aurora B kinase, two explore 
its roles in specific stages of mitosis and cytokinesis: Krenn and Musacchio offer a detailed 
review on the role of Aurora B in chromosome bi-orientation and spindle checkpoint signaling; 
whereas D’Avino and Capalbo take us through a thorough analysis of the later roles of Aurora 
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kinase within the CPC, focusing on its roles in controlling the 
assembly of the cleavage furrow, central spindle, and midbody 
and analyzing the function of the complex in the control of 
abscission timing. Finally, the chapter by Lindon et al. reviews 
the ubiquitin-dependent proteolytic regulation of Aurora B in 
mitosis.
The lesser known member of the Aurora family, Aurora 
C kinase, is the subject of two reports that center in its role in 
meiosis (Yang et  al.; Quartuccio and Schindler), the latter one 
also exploring in this context the significance of its expression in 
cancer cells (Quartuccio and Schindler).
As an important part of this Research Topic, we wanted to 
include in an overview of different aspects of the use of Aurora 
kinase as targets for drug development. D’Assoro et  al. have 
reviewed the potential of Aurora A as a therapeutic target in 
cancer, while Bavetsias and Linardopoulos have summarized 
the properties of the known Aurora kinase inhibitors currently 
in the clinic and have discussed current and future directions of 
such research. The contribution of de Groot and colleagues has 
given us an invaluable study of 10 commercially available Aurora 
inhibitors, including a set of “guidelines” for their efficient use 
in cell biology experiments (de Groot et al.). A group from Lilly 
Research Laboratories (Marugán et  al.) contributes a useful 
technical manuscript describing phenotypic screening assays 
to develop Aurora kinase inhibitors. Niu et  al. from Takeda 
Pharmaceuticals review the use of Alisertib (the highly specific 
Aurora A kinase inhibitor in advanced trials) in cancer therapy. 
Finally, in this section, the contribution from Nikonova et  al. 
explores the potential of combined therapy directed against both 
Aurora A and EGFR for the treatment of autosomal-dominant 
polycystic kidney disease.
We also wanted to have a flavor of some of the non-canonical 
roles of Aurora kinases outside of mitosis. We have managed to 
capture some of this activity in the article by Hascoet et al., who 
have reviewed some of these unconventional functions of Aurora 
kinases in kidney tumorigenesis.
We hope that the efforts of our authors and referees will find 
value in the field as we feel that this series of articles “Aurora 
kinases: classical mitotic roles, non-canonical functions, and 
translational views” represents an impressive snapshot of our 
current knowledge of the different functions of Aurora kinases. 
Written by experts in the field, we hope that this collection will 
inspire new research projects that will lead to a better understand-
ing of the role of these kinases in cancers.
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